Production of ULBP1-KO pigs with human CD55 expression using CRISPR technology

References

• Brostoff J. 2012. Immunology. 8th ed. London: Elsevier Science Publishers.
   Google Scholar
• Cooper DK. 2012. A brief history of cross-species organ transplantation. Proc (Bayl Univ Med Cent). 25:49–57. doi:10.1080/08998280.2012.11928783.
   PubMedGoogle Scholar
• Cooper DK, Ekser B, Ramsoondar J, Phelps C, Ayares D. 2016. The role of genetically engineered pigs in xenotransplantation research. J Pathol. 238:288–299. doi:10.1002/path.4635.
   PubMed Web of Science ®Google Scholar
• Delves PJ. 1998. Encyclopedia of immunology. 2nd ed. London: Elsevier Science Publishers.
   Google Scholar
• Fischer K, Kraner-Scheiber S, Petersen B, Rieblinger B, Buermann A, Flisikowska T, Flisikowski K, Christan S, Edlinger M, Baars W, et al. 2016. Efficient production of multi-modified pigs for xenotransplantation by ‘combineering’, gene stacking and gene editing. Sci Rep. 29(6):29081. doi:10.1038/srep29081.
   Google Scholar
• Ganji MR, Broumand B. 2007. Acute cellular rejection. Iran J Kidney Dis. 1(2):54–56.
   PubMedGoogle Scholar
• Gustavsson I. 1988. Standard karyotype of the domestic pig. Committee for the standardized karyotype of the domestic pig. Hereditas. 109(2):151–157. doi:10.1111/j.1601-5223.1988.tb00351.x.
   PubMed Web of Science ®Google Scholar
• Hryhorowicz M, Zeyland J, Słomski R, Lipiński D. 2017. Genetically modified pigs as organ donors for xenotransplantation. Mol Biotechnol. 59(9–10):435–444. doi:10.1007/s12033-017-0024-9.
   PubMed Web of Science ®Google Scholar
• Jura J, Smorąg Z, Słomski R, Lipiński D, Gajda B. 2007. Factors affecting the production of potential transgenic pigs by DNA microinjection; a six-year retrospective study. J. Anim. Feed Sci. 16(4):636–645. doi:10.22358/jafs/66820/2007.
   Web of Science ®Google Scholar
• Langford GA, Yannoutsos N, Cozzi E, Lancaster R, Elsome K, Chen P, Richards A, White DJ. 1994. Production of pigs transgenic for human decay accelerating factor. Transplant Proc. 26(3):1400–1401.
   PubMed Web of Science ®Google Scholar
• Lilienfeld BG, Garcia-Borges C, Crew MD, Seebach J. 2006. Porcine UL16-binding protein 1 expressed on the surface of endothelial cells triggers human NK cytotoxicity through NKG2D. J Immunol. 177:2146–2152. doi:10.4049/jimmunol.177.4.2146.
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Kärre K. 1990. In search of the ‘missing self': MHC molecules and NK cell recognition. Immunol Today. 11(7):237–244. doi:10.1016/0167-5699(90)90097-S.
   PubMedGoogle Scholar
• Ma Y, Zhang L, Huang X. 2014. Genome modification by CRISPR/Cas9. FEBS J. 281(23):5186–5193. doi:10.1111/febs.13110.
   PubMed Web of Science ®Google Scholar
• Niemann H, Verhoeyen E, Wonigeit K, Lorenz R, Hecker J, Schwinzer R, Hauser H, Kues WA, Halter R, Lemme E, et al. 2001. Cytomegalovirus early promoter induced expression of hCD59 in porcine organs provides protection against hyperacute rejection. Transplantation. 72:1898–1906. doi:10.1097/00007890-200112270-00006.
   PubMed Web of Science ®Google Scholar
• Niu D, Wei H-J, Lin L, George H, Wang T, Lee I-H, Zhao H-Y, Wang Y, Kan Y, Shrock E, et al. 2017. Inactivation of porcine endogenous retrovirus in pigs using CRISPR-Cas9. Science. 357(6357):1303–1307. doi:10.1126/science.aan4187.
   PubMed Web of Science ®Google Scholar
• Rieblinger B, Fischer K, Kind A, Saller BS, Baars W, Schuster M, Wolf-van Buerck L, Schäffler A, Flisikowska T, Kurome M, et al. 2018. Strong xenoprotective function by single-copy transgenes placed sequentially at a permissive locus. Xenotransplantation. 25(2):e12382. doi:10.1111/xen.12382.
   PubMed Web of Science ®Google Scholar
• Shifrin N, Raulet DH, Ardolino M. 2014. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol. 26(2):138–144. doi:10.1016/j.smim.2014.02.007.
   PubMed Web of Science ®Google Scholar
• Shimizu I, Smith NR, Zhao G, Nedof E, Sykes M. 2006. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation. 81:95–100. doi: 10.1097/01.tp.0000188176.18666.68
   PubMed Web of Science ®Google Scholar
• Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J. 2014. CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet. 52(5):289–296. doi:10.1136/jmedgenet-2014-102968.
   Web of Science ®Google Scholar
• Yang YG, Sykes M. 2007. Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol. 7(7):519–531. doi:10.1038/nri2099.
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, Lin G, Coudert JD, Stannard KA, Zitvogel L, et al. 2017. A2AR Adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 78(4):1003–1016. doi:10.1158/0008-5472.CAN-17-2826.
   PubMed Web of Science ®Google Scholar
• Zeyland J, Hryhorowicz M, Nowak-Terpiłowska A, Jura J, Słomski R, Smorąg Z, Lipiński D. 2018. The production of UL16-binding protein 1 targeted pigs using CRISPR technology. 3 Biotech. 8(1):70. doi:10.1007/s13205-018-1107-4.
   PubMedGoogle Scholar
• Zeyland J, Lipiński D, Słomski R. 2012. Human CD46, CD55 and CD59 expression influence on swine transgenic fetal fibroblasts’ survivability in the presence of human complement components. Ann Anim Sci. 12(4):515–526. doi:10.2478/v10220-012-0043-1.
   Web of Science ®Google Scholar
• Zhang F, Wen Y, Guo X. 2014. CRISPR/cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 23:40–46. doi:10.1093/hmg/ddu125 doi: 10.1093/hmg/ddt394
   PubMed Web of Science ®Google Scholar
• Zhou CY, McInnes E, Copeman L, Langford G, Parsons N, Lancaster R, Richards A, Carrington C, Thompson S. 2005. Transgenic mice expressing human CD59, in combination with human membrane cofactor protein and human decay-accelerating factor. Xenotransplantation. 12:142–148. doi:10.1111/j.1399-3089.2005.00209.x.
   PubMed Web of Science ®Google Scholar